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Abstract 
 
Introduction: The HOX genes are a family of closely related transcription factors that 
help to define the identity of cells and tissues during embryonic development and which 
are also frequently deregulated in a number of malignancies, including breast cancer. 
Whilst relatively little is known about the roles that individual HOX genes play in cancer, 
it is however clear that these roles can be both contradictory, with some members acting 
as oncogenes and some as tumor suppressors, and also redundant, with several genes 
essentially having the same function. 
Methods: Here we have attempted to address this complexity by using the HXR9 peptide 
to target the interaction between HOX proteins and PBX, a second transcription factor 
that serves as a common co-factor for many HOX proteins.  
Results: We show that HXR9 causes apoptosis in a number of breast cancer-derived cell 
lines and that sensitivity to HXR9 is directly related to the averaged expression of HOX 
genes HOXB1 through to HOXB9, providing a potential biomarker to predict the 
sensitivity of breast tumors to HXR9 or its derivatives. 
Conclusions: Measuring the expression of HOX genes HOXB1 to HOXB9 in primary 
tumors revealed that a subset of tumors show highly elevated expression indicating that 
these might be potentially very sensitive to killing by HXR9. Furthermore, we show that 
whilst HXR9 blocks the oncogenic activity of HOX genes, it does not affect the known 
tumor-suppressor properties of a subset of HOX genes in breast cancer. 
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Introduction 
 
The HOX genes are a family of homeodomain-containing transcription factors that were 
first identified as determinates of cell and tissue identity in early development, although 
they are now also known to function in adult stem cell renewal and differentiation [1-3]. 
A series of duplication events is thought to have given rise to the four separate clusters of 
HOX genes found in vertebrates, with each cluster consisting of a group of closely linked 
members that often share enhancer regions. These clusters are named A, B, C and D, and 
together they contain the 39 HOX genes found in mammals[4]. Each gene within a cluster 
is labeled with a number according to their relative position in the chromosome, so for 
example HOXB1 is the 3’ most member of the B cluster, and HOXB13 is the 5’ most 
member[5]. The linkage of genes within each cluster is closely reflected in both their 
temporal and spatial order of expression in the embryo, with the 3’ genes being expressed 
more anteriorly and earlier than their 5’ neighbors. The relative position within the cluster 
is also reflected in the co-factor interactions, DNA binding specificity and regulation of 
each member[4].  
 
In addition to a role in development, and subsequently in stem cell differentiation, the 
HOX genes are also frequently deregulated in a number of cancers including melanoma, 
mesothelioma, and lung, kidney, prostate, ovarian and breast cancer[6]. Their function in 
oncogenesis is still unclear; however it is apparent that the great complexity of HOX 
function in development is also reflected in oncogenesis, with some HOX genes 
functioning as tumor suppressors and others as oncogenes. The best known examples of 
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both have been identified in breast cancer, where HOXA5 is known to function as a tumor 
suppressor[7], at least in part through activating the transcription of the key tumor 
suppressor gene TP53[8]. Conversely, members of the closely related HOXB genes 
including HOXB5 and HOXB7 are oncogenic through mechanisms which include an up 
regulation of FGF2[9], and the promotion of epithelial to mesenchymal transition[10]. 
HOXB7 has also been shown to confer tamoxifen resistance through activation of the 
EGFR pathway[11]. Exactly how such similar transcription factors can have opposing 
functions is also unclear, although it may be related to differential co-factor binding and 
consequently differential regulation of target genes. Known co-factors include members 
of the PBX, MEIS and PREP families of transcription factors all of which can influence 
the binding selectivity of HOX proteins and their action as either a suppressor or activator 
of transcription[3]. As an additional complexity, HOX proteins can also regulate 
transcription through binding to DNA as monomers[12]. 
 
Whilst different HOX genes can have individual, specific functions in embryonic 
development, there is generally a high level of functional redundancy, especially with 
regards to fundamental and highly conserved patterning events such as anterior-posterior 
pattering of the spine and hindbrain[13, 14]. This is also true in cancer, where a similar 
oncogenic function is common to a number of HOX genes, especially HOXB1 through to 
HOXB9[14, 15].  
 
This mixture of opposing functionality and functional redundancy, combined with the 
lack of ligand binding sites, makes targeting HOX genes in cancer potentially very 
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difficult. One approach however is to target multiple groups of HOX genes in a way that 
also singles out specific HOX functions, something that could potentially be achieved by 
disrupting the binding of HOX proteins to specific co-factors. To date this has only been 
possible for the PBX co-factor that can bind to HOX proteins numbered 1 to 9[15-19]. 
PBX increases the nuclear translocation of HOX proteins and also influences the 
selection of DNA binding sites[20, 21]. Its interaction with HOX is mediated by a highly 
conserved hexapeptide region on HOX proteins[20-23] and previous studies have shown 
that a synthetic peptide consisting of these amino acids and a short polyarginine 
sequence, known as HXR9, is capable of blocking the interaction between HOX and 
PBX proteins both in vitro and in vivo. HXR9 causes apoptosis in a number of cancers 
including melanoma[15], myeloma[18], and kidney[16], non-small cell lung[17], and 
ovarian cancer[19]. Here we show that HXR9 also causes apoptosis in cell lines derived 
from different breast cancers, and that HXR9 specifically blocks the oncogenic function 
of HOX genes without blocking the known tumor-suppressor role of HOXA5. 
Importantly, we also show that there is an extremely high correlation between the average 
expression of HOX genes HOXB1 through HOXB9 and the sensitivity of cell killing by 
HXR9. 
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Materials and Methods 
 
Cell lines and culture 
The cell lines used in this study are listed in Supplementary Table 1. They were obtained 
from the ATCC through LGC Standards Ltd (UK), and were cultured according to the 
instructions on the LGC Standards website. 
 
Synthesis of HXR9 and CXR9 peptides 
HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide 
sequence that can bind to PBX and nine C-terminal arginine residues (R9) that facilitate 
cell entry[15]. The N-terminal and C-terminal amino bonds are in the D-isomer 
conformation, which has previously been shown to extend the half life of the peptide to 
12 hours in human serum[15]. CXR9 is a control peptide that lacks a functional 
hexapeptide sequence but which includes the R9 sequence. All peptides were synthesized 
using conventional column based chemistry and purified to at least 80% (Biosynthesis 
Inc, USA). 
 
Imaging of cell cultures 
Cells were plated in 6-well plates using 2 ml of medium and allowed to recover for at 
least 24 hours.  When approximately 60% confluent, cells were treated with the active 
peptide HXR9 (60 M) or the control peptide CXR9 (60 M) for 3 hours.  For phase 
contrast micrographs, the cells were washed twice with cold PBS and visualized using a 
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Nikon Eclipse TS100 inverted microscope and images recorded using a Nikon camera 
and capture software (Jencons).   
 
Analysis of cell death and apoptosis 
Cells were treated with HXR9 or CXR9 as described above.  Assessment of cell viability 
was done using the MTS assay (Promega) according to the manufacturer’s instructions.  
Cells were harvested by incubating in trypsin-EDTA (Sigma) at 37ºC until detached and 
dissociated.  Apoptotic cells were identified using flow cytometry (Beckman Coulter 
Epics XL Flow) and the Annexin V-PE apoptosis detection kit (BD Pharmingen) as 
described by the manufacturer’s protocol. Caspase-3 activity was measured using the 
EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the protocol defined by the 
manufacturer. 
 
RNA purification and reverse transcription 
Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen) by 
following the manufacturer’s protocol.  The RNA was denatured by heating to 65ºC for 5 
minutes.  cDNA was synthesized from RNA using the Cloned AMV First Strand 
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. 
 
Quantitative PCR 
Quantitative PCR was done using the Stratagene MX3005P real-time PCR machine and 
the Brilliant SYBR Green QPCR Master Mix (Stratagene).  Oligonucleotide primers were 
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designed to facilitate the unique amplification of-actin, c-Fos, TP53 and each HOX 
gene. 
 
Transcriptional profiling 
Total RNA was extracted from SKBR3 cells treated with CXR9 or HXR9 (60 µM) for 
three hours, and was used as a template to generate Cy3-labelled cRNA using the Low 
RNA Input Linear Amplification Kit (Agilent).  Each Cy3-cRNA was used as a probe on 
the Whole Human Genome Microarray (4x44K) slide.  This microarray consists of 60-
mer oligonucleotides with sequences representing more than 41,000 human genes.  The 
microarray slides were scanned and data were extracted using the Agilent Feature 
Extraction Software (version 9.5.3).  Data was analyzed using GeneSpring GX software. 
The full data set and further experimental details have been deposited in the Array 
Express repository; accession number E-MEXP-3634. 
 
Mice and in vivo trial 
All animal experiments were conducted in accordance with the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) guidelines for the Welfare of 
Animals in Experimental Neoplasia[24] and were approved by the University of Surrey 
Research Ethics Committee. The mice were kept in positive pressure isolators in 12 hour 
light / dark cycles and food and water were available ad libitum. 
Athymic nude mice were inoculated subcutaneously with a suspension of 2.5 x 
10
6
 MDA-MB231 cells in culture media (100 µl).  Once tumors reached volumes of 
approximately 100 mm
3
, mice received an initial dose of 100 mg/Kg CXR9 or HXR9 
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intratumorly, with subsequent dosing when or if the tumor reoccurred.  Each treatment 
group contained 10 mice. The mice were monitored carefully for signs of distress, 
including behavioral changes and weight loss.  
 
Patient samples 
Patient breast tissue samples and clinico-pathological data were obtained from the Guy’s 
and St Thomas’ (GST) Breast Tissue and Data Bank, London, UK (REC ref: 
07/H0804/131).This collection has approval from the GST Research Ethics Committee 
(ref: 07/H0804/131) and adheres to the Helsinki Declaration. Patients had given consent 
for the inclusion of their tissue in this bank; individual permission from each patient was 
not subsequently required for the particular study described here. Frozen sections were 
cut and using a stained guide slide, malignant cells were dissected from the surrounding 
tissue. RNA was extracted using the AllPrep DNA/RNA Micro kit (Qiagen). The 
manufacturer instructions were followed with the exception of an enhanced 
homogenization step.  
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Results 
 
HOX gene expression in breast cancer cell lines and normal breast tissue 
In order to assess the expression of HOX genes in breast cancer and in normal breast 
tissue five breast cancer-derived cell lines were used, SKBR3, MB231, MCF7, ZR75.1 
and UACC, together with MCF10a, derived from a non-malignant mammary epithelium 
(detailed in Supplementary Table 1). RNA was extracted from cultures of each of these, 
together with normal breast tissue. HOX expression was determined by semi-quantitative 
PCR, and calculated as a ratio with the expression of the house keeping gene GAPDH 
(Fig 1). This reveals a significant, but variable degree of HOX deregulation between 
breast cancers derived cell lines and normal breast tissue, with normal breast tissue and 
the non-malignant cell line MCF10a generally having lower expression than the cancer 
derived cell lines.  
 
HXR9 is toxic to breast cancer cells 
Previous studies have indicated that HXR9 is taken up by and is selectively cytotoxic to 
cancer cells. A fluorescently labeled derivative of HXR9 was incubated with MDA-
MB231 cells and localized to both the cytoplasm and the nucleus (Fig 2a). In order to 
determine the IC50 for cell killing by HXR9 we used an MTS assay at varying 
concentrations of the peptide. This indicated that the IC50 for cell killing for SKBR3, 
MDA-MB231, MCF7, ZR75.1, UACC and MCF10a were 16M, 23M, 33M, 42M, 
48M and 51M, respectively. Thus MCF10a and the breast cancer derived cell lines 
UACC, ZR75.1 and MCF7 are relatively insensitive to HXR9 whilst MDA-MB231 and 
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SKBR3 are significantly more sensitive (p<0.01; Fig 2b). As a control a second peptide 
was used, CXR9, which has an identical polyarginine cell penetrating sequence to HXR9 
but which lacks an active hexapeptide sequence. None of the cell lines were sensitive to 
CXR9 (i.e. IC50 > 100M). 
 
Treatment with HXR9 increases the expression of cFos but not TP53 
Previous studies have shown that HOX genes can prevent apoptosis, at least in part, by 
blocking the expression of cFos, and that HXR9 can induce apoptosis by mediating a 
rapid increase in the number of cFos transcripts[15]. SKBR3 and M cells similarly show 
a very large increase in cFos expression (553 fold) two hours after HXR9 treatment (Fig 
3). Conversely, some HOX genes have been identified as potential tumor suppressors, 
most notably HOXA5 in breast cancer through its regulation of TP53[8].  The detailed 
mechanism for this regulation is yet to be elucidated, but if it requires a HOXA5 / PBX 
dimer then it might be expected that HXR9 could reduce TP53 expression and therefore 
be pro-oncogenic in this respect. In order to determine whether this is the case we 
assayed TP53 expression in SKBR3 and MDA-MB231 cells treated with HXR9 by semi-
quantitative PCR. This revealed that there is no significant change in TP53 expression in 
response to HXR9 treatment in either cell line (Fig 3). 
 
HXR9 primarily causes transcriptional activation 
In order to identify additional target genes that are regulated by a HOX/PBX dimer, and 
are thus differentially expressed upon treatment with HXR9, we used whole genome 
based microarray to study the transcriptome of HXR9 treated SKBR3 cells. This revealed 
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that the majority of HXR9 target genes identified are upregulated by HXR9 treatment 
(Fig S1), indicating that the HOX / PBX dimers act predominantly to repress 
transcription in these cells. The promoter regions of the 20 genes that are most strongly 
upregulated by HXR9 were analyzed for the presence of the HOX / PBX binding 
consensus[25]. Of these 20 genes 18 had at least one potential site, and many of the 
promoter regions had multiple and often overlapping consensus binding sites (Fig S2), 
including ATF3, NR4A3, ZFP36 and PPP1R15A, that have tumor suppressor functions 
(Supplementary Table 2). Furthermore, amongst those genes that were upregulated by ten 
fold or more, 22 have known tumor suppressor function (Supplementary Table 2). 
 
HXR9 induces apoptosis 
The mechanism of cell death was studied in the most sensitive of six cell lines, SKBR3. 
Previous studies have shown that HXR9 can induce apoptosis through, at least in part, a 
rapid increase in expression of cFos[15]. SKBR3 and MDA-MB231 cells similarly show 
a very large increases in cFos expression (553 and 19.3 fold, respectively) two hours after 
HXR9 treatment (Fig 3). In order to establish whether HXR9 induces apoptosis, HXR9 
treated cells were analyzed by FACS after staining with Annexin-7AAD and propidium 
iodide. The former allows the detection of changes in the cell membrane that are 
characteristic of apoptosis, whilst the later is used to evaluate membrane integrity (Fig 
4a). This shows that HXR9 treated SKBR3 undergo cell death predominantly through 
apoptosis, with the majority of cells being in an early stage of apoptosis two hours after 
HXR9 treatment (Fig 4b). There is also a corresponding increase in Caspase 3 activity 
 13 
over two hours with the same concentration of HXR9 (Fig 4c). Similar results were 
obtained for the MDA-MB231 cell line (not shown). 
 
Sensitivity to HXR9 correlates with HOX expression 
As HXR9 targets the HOX / PBX interaction, we calculated the average expression of all 
HOX genes numbered between 1 and 9 (i.e. the 3’ most 27 members of the HOX family 
that bind PBX), for all of the cell lines and for normal breast tissue. When ranked against 
sensitivity to HXR9 there is an apparent positive relationship between mean HOX 
expression and IC50 with the exception of MCF7 (Fig 5a). However, when cell line 
sensitivity is ranked against mean expression of only the HOX genes HOXB1 through to 
HOXB9 the ranked order is complete (Fig 5b). When mean expression of HOXB1 through 
HOXB9 is plotted against the IC50 for HXR9 toxicity a linear relationship is apparent, 
the line of regression for this putative relationship has an r
2
 value of 0.9778 (p=0.0002), 
(Fig 5c).  
 
HOX genes HOXB1 through to HOXB9 are highly expressed in a subset of primary 
breast tumors 
In order to explore the possible relevance of these findings to primary tumors we 
measured the transcripts of HOX genes HOXB1 through to HOXB9 in 78 primary tumor 
samples obtained from the GST Breast Tissue and Data Bank, the associated pathological 
characteristics of which are listed in Supplementary Table 3.  This revealed that whilst 
the majority of tumors expressed these genes to a relatively low level, a subset (7.4%) 
showed a highly elevated level of expression that could indicate that these cells would be 
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sensitive to killing by HXR9 (i.e. with an IC50 <1M, Fig 5d). High levels for HOXB1 
through to HOXB9 expression did not correlate with expression of the estrogen receptor 
(ER), progesterone receptor (PR), or HER2, nor with survival, tumor grade, or spread to 
axillary lymph nodes (Fig S3). There was however a positive association between low 
HOXB1 through to HOXB9 expression and mucoid or lobular histology (Fig S3). 
 
HXR9 retards tumor growth in vivo 
In order to assess the efficacy of HXR9 in vivo we established a xenograft model of 
MDA-MB231. Although these cells are less sensitive to killing by HXR9 than SKBR3, it 
is more widely used as a xenograft model (605 references in PubMed compared to 35 for 
SKBR3), and represents a form of breast cancer with a poor prognosis, having been 
derived from a tumor negative for HER2, ER and PR[26]. Tumors were initiated by 
injection of cells into the flank, and treatment was started when the average tumor 
volume had reached 100 mm
3
  with an initial dose of HXR9 of 20 mg/Kg intratumorally, 
followed by an additional dose if tumor growth reoccurred (with no more than one 
additional dose per animal). Tumor growth in HXR9 treated mice was retarded 7.5 fold at 
13 days compared to the control group (Fig 6a), and the HXR9 treated animals survived 
for significantly longer (88% survival at 30 days as compared to 0% for the control 
group, p=0.004; Fig 6b) RNA was extracted from tumors at the end of 32 days in order to 
measure cFos expression by QPCR; cFos was found to be expressed at an 18-fold higher 
level in tumors from HXR9 treated mice than in tumors from untreated mice (Fig 6c). 
Histological analysis of CXR9 and HXR9 treated tumors revealed extensive cell death in 
the later (Fig 6d). 
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Discussion 
 
In this study we have shown that HOX genes are generally deregulated in breast cancer, 
and mostly there is an increase in expression when compared to normal breast tissue or 
non-malignant MCF10a cells, although the exact pattern of expression varies between 
cell lines. The significance of the variation between cell lines is unclear, although the 
functional redundancy between HOX genes may mean that the net effect of HOX over 
expression is similar. There are however cases where cancer phenotype can be 
determined by specific HOX genes, for example in ovarian cancer HOXA11 expression 
confers a mucinous (as opposed to serous) phenotype[27], and distinct patterns of HOX 
expression are associated with lymphoblastoid myeloma[18]. 
 
We also show that treating breast cancer cell lines with the HOX / PBX inhibitor HXR9 
causes apoptosis in SKBR3 and is cytotoxic to all of the lines tested. This suggests, as it 
has done in studies on other cancers, that targeting the HOX / PBX dimer allows a 
specific subset of HOX functions to be modified, one of which includes the repression of 
apoptosis[15-19]. In the case of melanoma, apoptosis is induced in part through the 
induction of cFos[15], and a large increase in cFos expression is also observed in this 
study when SKBR3 cells are treated with HXR9. Selective targeting of anti-apoptotic 
functions is important as some HOX genes, notably HOXA5 in breast cancer[8], have a 
tumor-suppressor role rather than an oncogenic role. This is mediated by an increase in 
TP53 expression[8], however we show here that HXR9 does not change TP53 expression 
in breast cancer cells, suggesting that the regulation of TP53 by HOXA5 does not depend 
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upon a HOXA5 / PBX dimer, but may instead be dependant on other co-factors, or may 
possibly not require a co-factor. The later possibility is supported by the observation that 
forced expression of HOXA5 alone is sufficient to drive TP53 transcription, and that the 
HOXA5 binding site identified in the TP53 promoter does not appear to include a PBX 
binding consensus[8]. Further, whilst confirming a positive interaction between HOXA5 
and TP53, a more recent study also suggests that TP53 is not transcriptionally regulated 
by HOXA5[28]. These findings support the conclusions of previous studies that indicate 
the HOX / PBX dimers are predominantly anti-apoptotic in the context of cancer[15-19]. 
 
An oncogenic role for HOX / PBX dimers is also supported by the transcriptional 
repression of genes with known tumor suppressor functions, all of which exhibit a 
correspondingly large increase in expression upon HXR9 treatment (Table 2). These 
include EGR2[29] and ATF3[30], both of which function in p53 mediated apoptosis, the 
GTPase encoding gene RRAD which is frequently lost in malignancy[31], and the EGFR 
/ ERBB2 inhibitor ERRFI1[32]. These findings are of particular interest because they 
suggest potential synergistic interactions between HXR9 and other classes of drug. 
 
Identifying patients that are likely to respond to a particular treatment is a now a key 
requirement in clinical trials, and the development of predictive biomarkers for this 
purpose is most effective at early drug development stages. We hypothesized that 
sensitivity to HXR9 in breast cancer lines should depend, at least to some extent, on HOX 
gene expression. Given the functional redundancy found in the PBX binding HOX 
proteins, we examined whether sensitivity might depend on the averaged level of HOX 
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gene expression. In fact, our results suggest that this is not the case. However, the 
averaged expression level of a subset of HOX genes, namely HOXB1 through HOXB9, 
does correlate with sensitivity to HXR9 with a highly significant line of regression. High 
levels of HOXB1 through HOXB9 expression are associated with increased sensitivity to 
killing by HXR9, whilst low levels of expression are associated with insensitivity to 
HXR9. Here we show that both normal breast tissue and the non-malignant mammary 
line MCF10a have relatively low levels of expression, and the later is also relatively 
resistant to HXR9 mediated cell killing.  
 
Conclusions 
The significance of these finding requires further study, although we note that HOXB 
genes have in general been more frequently implicated as having a role in cancer, both 
through direct mechanistic studies[6] and through a number of clinical observations 
including the association of elevated HOXB7 expression with a poor prognosis in HER2 
positive breast cancer[33]. Our analysis of 78 primary breast tumors showed that whilst 
the majority had relatively low levels of HOXB1 through to HOXB9 expression, a subset 
had very highly elevated expression of these genes, indicating that they could potentially 
be extremely sensitive to HXR9. Determining the expression of these genes from 
biopsies could form the basis by which patients might be selected for treatment by 
HXR9, or its derivative.  
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Figure Legends 
 
Figure 1. HOX gene expression in breast cancer derived cell lines and in normal 
breast tissue. The expression of each gene was determined by semi-quantitative PCR 
and is shown relative to the house keeping gene GAPDH (x10000). The values shown are 
the mean of three independent experiments and the error bars represent the SEM. NBT – 
normal breast tissue. 
 
Figure 2. (a) HXR9 enters the cytoplasm and nuclei of MDA-MB231 cells in vitro. 
MDA-MB231 cells were incubated with 22M FITC labeled HXR9 (green) for two 
hours and then stained with DAPI (a fluorescent dye staining nuclei blue). Scale bar: 5m 
(b) IC50 values for HXR9 treatment. The negative control peptide CXR9 was not toxic 
at any of the concentrations tested for any of the cell lines (i.e. the IC50 > 100M). Error 
bars represent the SEM (n=3), the p values are shown where p<0.01 with respect to 
MCF10a.  
 
Figure 3. Semi-quantitative PCR of TP53 and cFos in HXR9 treated SKBR3 (a) and 
MDA-MB231 (b) cells. RNA was extracted from cells cultured in vitro and treated with 
60M peptide for two hours. Results are expressed as a ratio with the housekeeping gene 
GAPDH and are the mean of 3 independent experiments, error bars show the SEM. *** 
p<0.001 with respect to untreated cells 
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Figure 4. HXR9 induces apoptosis in SKRB3 cells. SKBR3 cells were treated with 
60M HXR9 or CXR9 for two hours and cells were assessed for apoptosis or necrosis 
through Annexin / Propidium iodide staining. (a) Example plots for each treatment. (b) 
The % of cells in early apoptosis (EA), late apoptosis (LA), necrosis (N), or which are 
still viable (V) is shown. (c) Caspase 3 activity in SKBR3 cells treated with 60M HXR9 
or CXR9 for two hours. Cells lysates were treated with a Caspase inhibitor (Ac-DEVD-
CHO) to establish background signal (‘-AcDEVD’, ‘+AcDEVD’, lysates untreated / 
treated with inhibitor). Error bars show the SEM. *p<0.05, **p<0.01 with respect to 
untreated cells 
 
Figure 5. The IC50s for HXR9-treated breast cancer derived cell lines correlate with 
the mean expression of HOX genes HOXB1 through to HOXB9. (a) The mean 
expression of all HOX genes or (b) of HOX genes HOXB1 to HOXB9 were calculated and 
are shown for each cell line. The cell lines are arranged in order of decreasing sensitivity 
to HXR9 and the IC50 for each cell line is shown below the chart. Data are the mean of 
three independent experiments, error bars show the SEM. * p<0.0073 (applying 
Bonferonni’s correction for multiple hypothesis testing), as compared to SKBR3. P 
values are not shown where p>0.1. NBT – normal breast tissue. (c) Linear regression of 
cell line IC50s and mean HOX expression. The IC50 values for cell killing by HXR9 
were plotted against the mean expression level of HOX genes HOXB1 through to HOXB9 
for each of the cell lines tested. A linear regression (solid line) gives an r
2
 value of 
0.9778. The probability for the null hypothesis that the slope of the line is actually zero 
was calculated as to be p = 0.0002. NBT – normal breast tissue. (d) The distribution of 
 29 
mean HOXB1 through to HOXB9 expression in primary tumors. The expression of these 
genes in 78 primary tumors (red) were plotted according to their theoretical sensitivity to 
HXR9, as determined using the linear regression described above. The regression line 
shown in part (c) is included for reference. 
 
Figure 6. HXR9 retards MDA-MB231 tumor growth in vivo. (a) Growth curve for 
MDA-MB231 tumors treated intratumorally with a single dose of HXR9 or CXR9 when 
the tumor volume reached 100mm
3
. Error bars show the SEM. (b) Survival plot for 
HXR9 and CXR9 treated tumors shown in (a). (c) Expression of cFos in tumors treated 
with HXR9 or CXR9, shown as a ratio between cFos and GAPDH transcripts detected by 
QPCR. Error bars show the SEM. (d) Section through MDA-MB231 tumors in mice 
treated with CXR9 or HXR9. The CXR9 treated section shows highly undifferentiated 
tumor cells, whilst the HXR9 section shows the remains of dead tumor cells (T) 
surrounded by stroma (S). Scale bar: 20m. 
 
Supplementary figure 1. Changes in expression of HXR9 target genes in SKBR3 
cells. The relative expression of target genes are shown as a normalized intensity value 
(Log10), blue lines represent targets that increase expression in response to HXR9 
compared to untreated cells [Unt], whilst the red lines represent targets that are repressed 
by HXR9. 
 
Supplementary figure 2. Distribution of HOX/PBX consensus sites in the promoter 
regions of the 20 most responsive HXR9 target genes. Possible HOX / PBX consensus 
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binding sites are shown shaded according to the number of nucleotides that match the 
consensus (out of a maximum of 10). *Multiple consensus sites that overlap each other. 
 
Supplementary figure 3. The mean expression values of HOX genes HOXB1 through to 
HOXB9 in primary tumors grouped according to (a) histopathological type, (b) estrogen 
receptor (ER) status, (c) spread to nodes as determined by pathology, (d) 5 year survival, 
(e) grade (G2, grade 2; G3, grade 3), (e) whether tumors were from the left or right 
breast, (g) progesterone receptor status (PR), and HER2 status. Error bars show the SEM. 
 
Supplementary table 1. Summary of breast cancer derived cell lines used in this 
study. 
 
Supplementary table 2. Genes with potential tumor suppressor functions that are 
upregulated by HXR9.  
 
Supplementary table 3. Summary of pathological data for the primary tumors 
analyzed in this study. 
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